The Valley Desk

ArticleJournal of managed care & specialty pharmacyPublished

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of managed care & specialty pharmacy
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm, Residual; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Cost-Benefit Analysis; United States; Male; Bortezomib; Lenalidomide
PubMed ID
40952913
PubMed Central ID
PMC12577728
Added to directory
Source checked

Report a correction or request removal